World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
54107
World Ranking
5477
National Ranking
541

Anas Younes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anas Younes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 725 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Anas Younes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anas Younes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Anas Younes is affiliated with AstraZeneca in the United Kingdom and has an extensive publication record in the fields of medicine, biochemistry, genetics, and molecular biology. Their research primarily focuses on pathology and forensic medicine, oncology, molecular biology, genetics, and pulmonary and respiratory medicine.

Their main research topics include:

  • Lymphoma Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Protein Degradation and Inhibitors

Younes has contributed extensively to several prominent scientific venues, including:

  • Blood
  • Blood Advances
  • Journal of Clinical Oncology
  • Leukemia & Lymphoma/Leukemia and Lymphoma
  • Haematologica

Their recent papers demonstrate a focus on lymphoma and cancer therapies, with notable publications such as:

  • Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups (2020, Blood Cancer Journal)
  • Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma (2020, Cancer Discovery)
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial (2021, The Lancet Haematology)
  • OncoTree: A Cancer Classification System for Precision Oncology (2021, JCO Clinical Cancer Informatics)
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies (2020, Blood Advances)

Anas Younes collaborates frequently with a group of researchers including:

  • Connie Lee Batlevi
  • Andrew D. Zelenetz
  • David J. Straus
  • Matthew J. Matasar
  • Alison J. Moskowitz

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists

    Marilyn M. Li;Michael Datto;Eric J. Duncavage;Shashikant Kulkarni

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    Anas Younes;Nancy L Bartlett;John P Leonard;Dana A Kennedy

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review

    Bertrand Coiffier;Arnold Altman;Ching-Hon Pui;Anas Younes

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

    Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro

  • Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.

    Mitchell S. Cairo;Bertrand Coiffier;Alfred Reiter;Anas Younes

  • Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta

    Shalini Mathias;Anas Younes;Chu-Cheng Kan;Irene Orlow

  • Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

    Issa F. Khouri;Rima M. Saliba;Sergio A. Giralt;Ming Sheng Lee

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • Brentuximab Vedotin (SGN-35)

    Jessica Katz;John E. Janik;Anas Younes

  • Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

    I F Khouri;J Romaguera;H Kantarjian;J L Palmer

  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Robert Chen;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    David Sanghyun Hong;Razelle Kurzrock;Youngsoo Kim;Richard Woessner

  • Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

    Koen van Besien;Chul S. Ha;Sandy Murphy;Peter McLaughlin

  • Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

    Peter McLaughlin;Fredrick B. Hagemeister;Jorge E. Romaguera;Andreas H. Sarris

Frequent Co-Authors

Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Larry W. Kwak
Larry W. Kwak City Of Hope National Medical Center
Craig H. Moskowitz
Craig H. Moskowitz University of Miami
David J. Straus
David J. Straus Memorial Sloan Kettering Cancer Center
Fernando Cabanillas
Fernando Cabanillas The University of Texas MD Anderson Cancer Center
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in alternative routes to a healthcare career, online degrees offer flexible options beyond the traditional medical school path. Many aspiring nurses and practitioners turn to programs that allow faster, more accessible advancement.

Nurses looking to earn a Bachelor of Science in Nursing might consider an rn to bsn online with no clinicals option, which eliminates on-site requirements for those with existing RN credentials. On the other hand, if you are aiming for advanced practice and leadership roles, the shortest online dnp program can be a direct pathway, especially for working professionals.

For even more convenience, some online dnp programs without clinicals remove or reduce in-person training, making it easier for those with experience to progress their skills. Meanwhile, entry-level students may benefit from enrolling in a accelerated lpn program online, jumpstarting their nursing careers in less time.

These varied online degree options highlight the evolving and expanding career pathways in medicine, making healthcare education more accessible than ever.

Best Scientists Citing Anas Younes

Trending Scientists